Congress creates federal drug factory to bypass pharma pricing

What it does

This bill creates a new National Institute for Biomedical Research and Development within the NIH to conduct full-cycle drug, device, and biological product development with the explicit goal of making medicines available to the public at equitable and accessible prices. The Institute would own patents and trade secrets from federally funded research, license them to the Medicines Patent Pool and other entities under cost-plus and non-exclusive terms, conduct public manufacturing where practicable, and share all clinical trial data and research findings transparently. A 15-member governing board with strict conflict-of-interest rules (excluding pharma lobbyists, executives from companies with federal settlements, and those with financial interests) would oversee priorities focused on unmet public health needs rather than market profitability.

Why we flagged it

The bill's core mechanism is establishing a federal institute to develop and manufacture medicines at cost, own resulting patents, and license them under terms that prioritize public access over private profit. This is fundamentally a public-sector drug development and pricing control measure, not a subsidy or deregulation.

What the text implies

• The bill grants the federal government ownership of all patents and trade secrets from federally funded research, including work conducted through private contractors—a significant shift in IP allocation that may deter some private R&D partnerships unless the public interest licensing terms prove attractive.
• Mandatory licensing to the Medicines Patent Pool and non-exclusive terms for for-profit entities may reduce incentives for private pharmaceutical companies to participate in Institute-funded research or to license resulting patents, potentially fragmenting the drug development ecosystem.
• The requirement to share all clinical trial data and safety information without trade secret protection could accelerate generic competition and lower prices, but may also reduce the commercial value of patents held by the Institute, affecting royalty reinvestment into future R&D.
• The governing board's strict conflict-of-interest rules (excluding pharma executives, lobbyists, and those from companies with federal settlements) may limit industry expertise on the board, potentially affecting technical decision-making on complex manufacturing and licensing questions.
• Public manufacturing 'if practicable' creates ambiguity about when the Institute will actually produce drugs versus licensing to private entities, leaving room for discretionary decisions that could undermine the cost-control objective.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary citizens gain direct access to lower-cost medicines through public manufacturing and non-exclusive licensing, transparent clinical data that enables informed decision-making, and research prioritized by public health need rather than profit. The bill restricts pharmaceutical industry influence over research priorities and pricing, shifting control toward public health officials, patient advocates, and civil society representatives.

Who stands to gain

• patients and consumers (lower medicine prices)
• public health programs (reduced drug costs)
• nonprofit organizations (free patent licenses)
• generic and biosimilar manufacturers (non-exclusive licensing)
• Medicines Patent Pool (preferred licensing partner)

Named in the bill

National Institute for Biomedical Research and Development, National Institutes of Health (NIH), Department of Health and Human Services, Medicines Patent Pool, Food and Drug Administration (FDA), Biomedical Advanced Research and Development Authority (BARDA), Walter Reed Pilot Bioproduction Facility, PubMed Central, National Library of Medicine

Where it stands

5 cosponsors: 5 Democrats.

• Mar 5, 2026 — Introduced · Congress.gov: “Introduced in House”
• Mar 5, 2026 — Referred to House Committee on the Judiciary and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $10,000 in lobbying spend. A filing names 16 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Rashida Tlaib, the sponsor, reported $42,050 in PAC receipts in the 2026 cycle.

• P Street Project, Inc. — $10,000 on 1 filing

Lobbying Disclosure Act filings through Jul 17, 2026. A filing shows who paid to lobby on a bill it names, not what changed.